CME Available: [ Ссылка ]

At the conclusion of this activity, participants will be able to:
1. Analyze breakthrough treatments in the management of advanced and metastatic hormone sensitive prostate cancer (mHSPC) and castration resistant prostate cancer (CRPC).
2. Identify the active agents and their mechanism of action in the management of mHSPC, nmCRPC and mCRPC.
3. Describe the indications, sequencing and combinations for treatment with approved agents in the management of mHSPC and nmCRPC.

This educational series is supported by independent educational grants from:
Astellas
AstraZeneca
Bristol Myers Squibb
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Merck
Pfizer, Inc
Sanofi Genzyme
UroGen Pharma, Inc.

свернуть